Clinical Trial Update: A Study of Trastuzumab and Pyrotinib in HER2 Positive Locally Advanced or Metastatic Urothelial Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating trastuzumab plus pyrotinib for HER2-positive urothelial carcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Urothelial Carcinoma

Drugs mentioned

• Pyrotinib (pyrotinib)
• Trastuzumab (trastuzumab)

Snippet

Sponsor: Chinese Academy of Medical Sciences | Conditions: Carcinoma, Transitional Cell, HER-2 Gene Amplification | Phase 2 | Status: UNKNOWN